Objective: To examine the efficacy and safety of combination therapy with exenatide plus pioglitazone vs basal/bolus insulin in patients with poorly controlled type 2 diabetes mellitus (T2DM) with very high hemoglobin A1c (HbA1c) (.10%) receiving sulfonylurea plus metformin and with a long duration of disease.
H yperglycemia is the major factor responsible for diabetic microvascular complications (i.e., retinopathy and nephropathy) (1) (2) (3) (4) . Every 1% decrease in hemoglobin A1c (HbA1c) is associated with an ;35% reduction in the incidence of retinopathy and nephropathy (1) (2) (3) (4) . Progressive b-cell failure is the principal pathophysiologic abnormality responsible for the development and progression of hyperglycemia in individuals with type 2 diabetes mellitus (T2DM) (5) . In addition to its role in the development of diabetic microvascular complications, chronic elevation in the plasma glucose concentration exerts a deleterious effect on b-cell function (i.e., glucotoxicity) (6), creating a negative feedback cycle that exacerbates the defect in insulin secretion. Studies in both experimental animals and in humans have demonstrated that chronic elevation in the plasma glucose concentration impairs b-cell function (7, 8) . Conversely, correction of hyperglycemia improves b-cell function in experimental animals and in patients with T2DM (9) (10) (11) (12) .
The progressive nature of diabetes, long duration of disease, markedly elevated HbA1c, and glucotoxic effect of chronic hyperglycemia on b-cell function have led to the dogma that, in subjects with a very high HbA1c (e.g., HbA1c .10%), insulin therapy is the treatment of choice (13, 14) . Independent of b-cell function, insulin therapy can effectively lower the plasma glucose concentration, ameliorate the glucotoxic effect of hyperglycemia on the b cell (9) (10) (11) , and reduce the HbA1c to 6.5% to 7.0% (10, 11) . On the basis of this rationale, the American Diabetes Association (ADA) (13) and the American Association of Clinical Endocrinologists (14) have recommended the institution of insulin therapy in poorly controlled T2DM with high HbA1c (.9% to 10%), especially in patients with clinical symptoms of hyperglycemia (e.g., polydipsia and polyuria).
Glucagonlike peptide-1 (GLP-1) receptor agonists (RAs) improve b-cell function by enhancing b-cell responsiveness to glucose (i.e., improved b-cell glucose sensitivity) (15) (16) (17) ; this beneficial effect on the b cell can be observed within 8 hours of a single injection of the GLP-1 RA (17) and persists for at least 4 years (16, 18, 19) . Thus, the GLP-1 RAs produce a rapid and durable reduction in HbA1c with a low risk of hypoglycemia. Thiazolidinediones, which were developed as insulin sensitizers, also have a potent effect on the improvement of b-cell function (20) (21) (22) (23) (24) (25) (26) , and clinical trials have demonstrated durable HbA1c reduction with low risk of hypoglycemia compared with sulfonylureas (26) . Because thiazolidinediones improve both insulin action and insulin secretion via mechanisms that are distinct from the GLP-1 RAs, we hypothesized that combination therapy with pioglitazone plus exenatide would effectively lower the plasma glucose concentration in patients with poorly controlled T2DM with a very high HbA1c and longstanding diabetes. This combination therapy could provide a therapeutic option to insulin for the treatment of patients with very high HbA1c. To address this question, we analyzed data from participants of the Qatar Study who had a baseline HbA1c .10% and compared the decrease in HbA1c from baseline to 6 months in subjects receiving combination therapy with exenatide plus pioglitazone vs basal/bolus insulin therapy.
Research Design and Methods
Study participants included all patients with T2DM in the Qatar Study who had a baseline HbA1c .10% (range, 10.0% to 15.1%) and manifested symptoms of hyperglycemia as evidenced by polydipsia and nocturia. The Qatar Study (27) is an open-label, single-center, randomized controlled trial (clinicaltrials.gov identifier NCT02887625) that examines the efficacy, durability, and safety of combination therapy with exenatide plus pioglitazone vs basal/bolus insulin therapy in patients with poorly controlled T2DM receiving metformin plus sulfonylurea. Patients with T2DM with poor glycemic control on maximal/near-maximal doses of metformin plus sulfonylurea were recruited to the study. Eligible subjects were randomly assigned to receive basal (glargine)/bolus (aspart) insulin therapy or weekly exenatide plus pioglitazone to achieve HbA1c ,7.0%. The study is an ongoing study and is being performed at Hamad General Hospital, Doha, Qatar. Herein, we report the efficacy (measured as the decrease in HbA1c from baseline to 6 months) of combination therapy with exenatide plus pioglitazone with respect to glycemic control compared with basal/bolus insulin therapy in subjects who had a starting HbA1c .10%. A total of 101 participants fulfilled the criteria for inclusion in the present report. The study protocol was approved by the Institutional Review Board of Hamad General Hospital, and informed written consent was obtained from all patients prior to enrollment.
Other than diabetes, patients were in good general health as determined by medical history and physical examination. Participants had normal kidney (creatinine ,1.4 mg/dL) and liver function (liver function test less than twice the upper normal level), serum chemistries, electrocardiogram, and urinalysis, and negative pregnancy tests. Body weight was stable (63 pounds) within the preceding year, and no subject participated in any excessively heavy exercise program. Exclusion criteria were hematocrit ,34%, medications known to affect glucose metabolism other than sulfonylureas and metformin, evidence of diabetic proliferative retinopathy, albumin excretion .300 mg/d, and major organ system disease as determined by physical examination, medical history, and screening blood tests. All patients received maximal/near-maximal therapy with metformin plus sulfonylurea.
Study design
Subjects were consecutively randomly assigned to receive combination therapy with pioglitazone (30 mg/d) plus exenatide (2 mg/wk) (combination therapy) or basal (glargine)/bolus (aspart) insulin (insulin therapy) to maintain HbA1c ,7%. Insulin therapy was started with insulin glargine before breakfast. The starting glargine dose as previously described (27) , and the dose was adjusted weekly to achieve a fasting plasma glucose (FPG) ,110 mg/dL. After achieving the FPG goal, if the HbA1c was .7.0%, 4 to 6 units of insulin aspart was started before each meal and the dose was adjusted to achieve a plasma glucose concentration ,140 mg/dL at 2 hours after meals. All subjects in the insulin therapy arm were receiving aspart insulin at 6 months. The insulin dose (both glargine and aspart) was adjusted weekly until the desired level of glycemic control was achieved or hypoglycemic events (see definition later) were encountered. The highest insulin dose after hypoglycemic events had resolved was continued as the therapeutic dose, and patients continued with their monthly followup visits.
After random assignment, patients were seen at months 1, 2, 3, 4, and 6, or more frequently on the basis of the plasma glucose concentration. The FPG, body weight, and HbA1c were measured at each follow-up visit, and the medication dose was adjusted to maintain FPG ,110 mg/dL, 2-hour-postmeal plasma glucose concentrations ,140 mg/dL, and HbA1c ,7%, unless hypoglycemia was encountered. Because the subjects were markedly hyperglycemic, the sulfonylurea dose was not reduced at the time of initiation of insulin therapy or combination therapy. Rather, it was prespecified that the sulfonylurea dose should be reduced if three minor hypoglycemic events occurred at two consecutive follow-up visits.
If hypoglycemia occurred (defined as more than three events on two consecutive visits), the sulfonylurea dose was reduced (by 30 mg/d for gliclazide and by 2 mg/d for glimepiride) at each follow-up visit until the hypoglycemia resolved. If, after discontinuation of sulfonylurea, patients in the insulin therapy group continued to experience hypoglycemia, the insulin dose was adjusted. If hypoglycemia was encountered in the combination therapy group (pioglitazone plus exenatide), the sulfonylurea dose was reduced as described for the insulin therapy group. The metformin dose was not reduced in any subject in either the insulin therapy or combination therapy group. Subjects who manifested hypoglycemia were seen weekly and the medication dose was adjusted (as described previously) according to home-measured blood glucose values until the hypoglycemia disappeared, after which the subjects continued with their monthly follow-up visits. Hypoglycemia was defined as blood glucose concentration ,60 mg/dL with or without symptoms or hypoglycemic symptoms that subsided following glucose ingestion. Blood glucose levels were measured by home blood glucose monitoring (OneTouch; LifeScan) and verified by the study coordinator on each follow-up visit. Subjects were asked to perform a seven-point home blood glucose profile once per week. During each follow-up visit, FPG was measured, records of home-measured glucose values were reviewed, and patients were questioned about symptoms of hypoglycemia. Severe hypoglycemia was defined as hypoglycemia requiring third party assistance.
Blood pressure and lipid-lowering medications were adjusted to achieve the goals recommended by the ADA: blood pressure ,140/90 mm Hg and low-density lipoprotein cholesterol ,100 mg/dL.
Data analysis and statistical analysis
The change in HbA1c from baseline to 6 months was compared in subjects receiving combination therapy vs insulin therapy. Secondary end points included: (1) percentage of subjects achieving HbA1c ,6.5% and ,7.0%; (2) decrease in FPG concentration; (3) change in body weight; and (4) rate of hypoglycemic events. Overall frequency of hypoglycemia was calculated as total number of hypoglycemic events divided by the number of patient-years of follow-up in each arm. The percentage of subjects experiencing hypoglycemia was calculated as the number of subjects experiencing at least a single event divided by the number of patients in that arm.
Values are presented as mean 6 standard error of the mean. The two-sided t test was used to compare mean differences between the two treatment arms. The x 2 test was used to test significance of discrete variables.
Results
In the Qatar Study, 101 patients had a baseline HbA1c .10%. Of these, 53 patients received combination therapy and 48 patients received insulin therapy. Table 1 presents the baseline characteristics of study participants. The two groups were well matched with respect to age, sex, body mass index, disease duration, and baseline HbA1c. The baseline HbA1c was 11.5% 6 0.2% and 11.2% 6 0.2% in the combination therapy and insulin therapy groups, respectively [P = not significant (NS)].
All patients were receiving background therapy with metformin plus sulfonylurea. The mean metformin dose was 1896 6 50 mg/d and 1978 6 30 mg/d in the combination and insulin therapy groups, respectively (P = NS). Fifty-eight percent and 55% of patients were receiving gliclazide and 42% and 45% of patients were receiving glimepiride in the combination therapy and insulin therapy groups, respectively.
At 6 months, all subjects in the insulin therapy group were receiving insulin glargine plus insulin aspart before meals. The mean insulin dose was 45 6 3 units of glargine (range, 22 insulin per day. All subjects in the combination therapy group were receiving 2 mg/wk of exenatide; the mean dose of pioglitazone was 33 6 1 mg/d. The metformin dose at 6 months was identical to the starting dose. However, the sulfonylurea dose was reduced to avoid hypoglycemia (defined as at least three minor events on two consecutive follow-up visits). In approximately 30% (n = 14) of subjects receiving insulin therapy, the sulfonylurea was discontinued (nine received gliclazide and five received glimepiride), and the dose was reduced in the other 70% (n = 34) to 82.5 6 6.5 mg/d and 4.1 6 0.4 mg/d of gliclazide and glimepiride, respectively (starting dose, 115 6 2 mg/d and 7.2 6 0.2 mg/d, respectively). Similarly, at 6 months, the sulfonylurea was discontinued in 11 subjects in the combination therapy arm (five received gliclazide and six received glimepiride), and the dose was reduced to 101.8 6 3.6 mg/d and 4.6 6 0.6 mg/d for gliclazide and glimepiride, respectively (starting dose, 113 6 3 mg/d and 7.4 6 0.2 mg/d, respectively). Figure 1 (a) depicts the change in HbA1c over 6 months. Subjects in the insulin therapy group experienced a reduction in HbA1c from 11.2% 6 0.2% at baseline to 7.4% 6 0.1% (ΔHbA1c, 23.8%) at 6 months. A more robust decrease in HbA1c from 11.5% 6 0.2% to 6.7% 6 0.1% (ΔHbA1c, 24.8%) was achieved in subjects receiving combination therapy [ Fig. 1(b) ]. At 6 months, there was a statistically significantly greater HbA1c decrement (1.0%; P , 0.001) in the combination therapy group.
More individuals receiving combination therapy achieved the ADA treatment goal (HbA1c ,7.0%) at 6 months vs subjects receiving insulin therapy (70% vs 35%; P = 0.003). Similarly, more patients achieved an HbA1c ,6.5% in the combination therapy group (53% vs 13%; P , 0.0001). Combination therapy was equally effective in lowering the HbA1c in all three ethnic groups (Qatari nationals, non-Qatari Arabs, and Asian Indians). The efficacy of combination therapy in lowering HbA1c was independent of age, sex, body mass index, or diabetes duration.
Fasting and postprandial glucose
Baseline FPG was similar in the combination therapy and insulin therapy groups (258 6 10 mg/dL vs 264 6 8 mg/dL, respectively; P = NS) and decreased rapidly after starting therapy [ Fig. 2(a) ] in both groups. The decrease in FPG was faster in subjects receiving insulin therapy than in subjects receiving combination therapy [ Fig. 2(a) ], and at month 1 the FPG concentration was significantly lower in the insulin therapy group (133 6 6 mg/dL vs 162 6 9 mg/dL; P , 0.05). However, after 1 month, the FPG was comparable in both treatment groups. The postprandial plasma glucose concentration at 6 months was significantly higher in subjects receiving insulin therapy than in subjects receiving combination therapy. The mean incremental area under the plasma glucose concentration curve during the daily glucose measurements (seven-point home blood glucose profile) in insulintreated subjects was almost twice as great as in subjects receiving combination therapy (609 6 35 mg/dL/h vs 312 6 13 mg/dL/h; P , 0.01) [ Fig. 2(b) ].
Body weight
The mean body weight increased in both treatment groups (Fig. 3) . However, subjects in the combination therapy group experienced half as much weight gain as subjects in the insulin therapy group (2.7 6 0.5 kg vs 5.3 6 0.6 kg; P = 0.002).
Adverse events
In general, both treatments were well tolerated and only a small number (,5%) of patients withdrew from the study because of adverse events. Approximately 90% of patients in both groups experienced at least one adverse event (Table 2) ; most adverse events were mild and unrelated to the study treatment. With regard to adverse events related to the study treatment, hypoglycemia was the most common and was reported by 83% and 56% of participants receiving insulin therapy and combination therapy, respectively (P , 0.0001). The overall frequency of hypoglycemic events was approximately 2.5-fold greater in the insulin therapy vs combination therapy group (5.8 vs 2.1 events per patient year; P , 0.0001) (Fig.  4) . All hypoglycemic events were mild; no severe hypoglycemia occurred in either group. Two subjects in the combination therapy group experienced a local reaction at the injection site. Subjects receiving combination therapy experienced more frequent gastrointestinal side effects and ankle edema. Thirty-seven percent of combination therapy subjects experienced nausea at the initiation of exenatide therapy; the nausea was mild and subsided after 2 to 3 months. Only one patient discontinued treatment due to nausea. The incidence of peripheral edema was low: 5.6% vs 13.5% in the insulin therapy and combination therapy groups, respectively. Peripheral edema was mild in all but one case and easily controlled with the addition of a distally acting diuretic. One patient discontinued combination therapy because of peripheral edema. There were no cases of congestive heart failure. The number of subjects who withdrew because of adverse events was small: two receiving combination therapy and none receiving insulin therapy.
Discussion
The major finding of this study is that combination therapy with pioglitazone plus exenatide is effective and safe in lowering HbA1c in symptomatic patients with poorly controlled T2DM and a very high HbA1c (HbA1c .10%) and longstanding disease (mean duration .10 years) treated with maximal/ near-maximal doses of metformin plus sulfonylurea. The ADA, the European Association for the Study of Diabetes (13), and the American Association of Clinical Endocrinologists (14) recommend starting patients with T2DM and high baseline HbA1c (.9.0%) and patients with symptoms of hyperglycemia on insulin therapy. Previous studies have demonstrated that chronic elevation of plasma glucose concentration exerts a deleterious action on b-cell function (i.e., glucotoxicity) (5-7). Thus, patients with T2DM and HbA1c .10.0% have a severe impairment in b-cell function and often respond poorly to the addition of other oral agents. Insulin is a powerful antihyperglycemic agent, and it rapidly lowers the plasma glucose concentration independent of b-cell function. Furthermore, restoration of euglycemia and reversal of glucotoxicity (9-11) and lipotoxicity (28) can lead to recovery of b-cell function. No previous study has compared the efficacy of insulin therapy with other antidiabetic regimens in patients with very high HbA1c (e.g., HbA1c .10%). The current study compared insulin therapy with another antidiabetic regimen in patients with a very high HbA1c and symptomatic hyperglycemia that includes polydipsia and nocturia (mean of 2.4 voids per night), and demonstrated that combination therapy with exenatide plus pioglitazone is as effective as insulin therapy in lowering the HbA1c in this patient population.
As anticipated, insulin produced a rapid decrease in the plasma glucose concentration, and the FPG concentration declined to the normal range at 1 month after the start of therapy, resulting in a marked reduction in HbA1c. With the combination of pioglitazone plus exenatide, the decline in FPG concentration and HbA1c was slower than with insulin therapy [ Fig. 2(a) ]. This is explained by the slower onset of action of pioglitazone and the time (4 to 6 weeks) required to reach steady-state plasma exenatide levels with the brand of exenatide used (Bydureon; AstraZeneca). Nonetheless, subjects receiving combination therapy were asymptomatic after 1 month. At month 2, the reductions in FPG concentration and HbA1c were similar in the combination and insulin therapy groups, and at months 3, 4, and 6, the reduction in HbA1c was significantly greater in subjects receiving combination therapy [ Fig. 1(a) ]. At month 6, the decrease in HbA1c from baseline in subjects receiving combination therapy (24.8%) was significantly greater (P , 0.001) than that in subjects treated with insulin (23.8%). More subjects receiving combination therapy achieved the ADA treatment goal of HbA1c ,7.0% (70% vs 35%; P , 0.001) with significantly less hypoglycemia. It should be noted that subjects in both treatment arms, despite very poor initial glycemic control (HbA1c .10%), experienced very good glycemic control at 6 months. These results demonstrate that combination therapy with exenatide plus pioglitazone is an effective therapeutic option for patients with poorly controlled T2DM and very high HbA1c (e.g., HbA1c .10%).
Despite a significantly lower HbA1c at 6 months, the combination therapy group experienced a significantly lower rate of hypoglycemia: 2.1 vs 5.8 events per patient per year (P , 0.001) (Fig. 4) . Reducing the sulfonylurea dose in the combination therapy group significantly decreased/ eliminated the incidence of hypoglycemia. It should be noted that the sulfonylurea dose was reduced similarly in both treatment groups to avoid hypoglycemia. Nonetheless, subjects in the insulin therapy group experienced a 2.5-fold greater incidence of hypoglycemia, which impeded further escalation of the insulin dose. It is possible that sulfonylurea has contributed to the high hypoglycemia rate in subjects receiving insulin therapy, and if sulfonylurea had been discontinued at random assignment in all subjects receiving insulin therapy, a lower rate of hypoglycemia could have been achieved. However, in such a scenario, a higher insulin dose would have been required to achieve the same level of glycemic control. It should be noted that the mean FPG concentration in insulin-treated subjects reached the target (110 mg/dL) at about 2 months, attesting to the rigorous insulin-intensification schedule. Nonetheless, the glycemic goal (HbA1c ,7.0%) was achieved in only one-third (35%) of the patients.
Other studies (29) (30) (31) (32) (33) have used different insulintitration algorithms for initiation of insulin therapy in patients with T2DM and reduced the mean HbA1c to ,7.0%. However, higher rates of hypoglycemia were observed in these studies. For example, the target HbA1c for the intensive treatment arm in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study (33) was 6.5%, and 25% of participants experienced severe hypoglycemia, whereas 10% required medical assistance to manage the hypoglycemia. Similarly, a large portion of patients in the studies by Bergenstal et al. (31) and Edelman et al. (32) experienced nocturnal hypoglycemia. Because the risk of hypoglycemia increases with the decrease in HbA1c, the caring physician always has to weigh the risk of hypoglycemia vs the benefit of further HbA1c reduction. In the current study, we prespecified the threshold for hypoglycemia at three minor events on two consecutive visits to minimize the risk of hypoglycemia, and, indeed, the incidence of hypoglycemia in both treatment arms was relatively low compared with other studies which used intensive insulin therapy. Nonetheless, despite a very high starting HbA1c (;11.5%), the vast majority of patients in both treatment arms achieved the ADA glycemic target (HbA1c ,7.0%) or their HbA1c had decreased to close to the target at 6 months, demonstrating that both treatment regimens (intensive basal/bolus insulin) and combination therapy with exenatide plus pioglitazone can safely be used in symptomatic patients with T2DM and a very high HbA1c (e.g., .10.0%).
In the current study, we used the algorithm developed by 4-T study investigators (30) to initiate insulin therapy, and unlike the 4-T study, subjects in the current study injected insulin glargine in the morning. It is possible that the timing of insulin injection in the current study may have contributed to the increased rate of hypoglycemia in the insulin arm compared with the combination therapy arm. However, a previous study (29) demonstrated that morning dosing of glargine is associated with a lower risk of hypoglycemia than bedtime dosing.
Subjects receiving combination therapy experienced half as much weight gain compared with subjects receiving insulin therapy (2.7 kg vs 5.3 kg). Although pioglitazone therapy resulted in weight gain on average, approximately one-third (29%) of patients receiving combination therapy experienced weight loss compared with only 2% (P , 0.01) in the insulin therapy group. This most likely is explained by the concomitant use of exenatide, which suppresses the appetite and promotes weight loss (15, 16, 19) . It should also be noted that with pioglitazone, the greater the weight gain, the greater the improvements in HbA1c, insulin sensitivity, and b-cell function (24) . The marked improvement in glycemic control and the removal of glycosuria could also have contributed to the weight gain in both treatment groups.
Both treatments were well tolerated and few subjects (,5% in the combination therapy and 0% in insulin therapy group) withdrew because of adverse events. The majority of adverse events were mild and unrelated to study treatment. Hypoglycemia was the most common adverse event. Compared with other studies that have used intensive insulin therapy in T2DM (24) (25) (26) , the rate of hypoglycemia was relatively low ( Table 2 ). The relatively low rate of peripheral edema (Table 2) with combination therapy most likely is explained by the lower dose of pioglitazone (30 mg/d) used in the current study and the natriuretic effect of exenatide. The majority of cases of edema were mild, and the edema was easily controlled with the addition of a distally acting diuretic to the treatment regimen. Only one subject discontinued combination therapy because of ankle edema. No cases of congestive heart failure or fractures occurred in either group.
There are several limitations to the current study. The therapies used (weekly exenatide and multiple daily insulin injections) prohibited blinding of the study medications. The study included a relatively small number of participants, primarily of Arab origin (;70% of participants). Thus, a larger multiethnic study is warranted to examine the generalizability of this treatment approach in individuals with poorly controlled and longstanding T2DM. Furthermore, longer follow-up is required to determine the durability of the glycemic control achieved using combination therapy. Nonetheless, the present results are impressive, and contrary to standard dogma, demonstrate that even in individuals with longstanding T2DM and very poorly controlled disease (HbA1c .10%), combination therapy with a GLP-1 RA plus pioglitazone can achieve near-normal/ normal HbA1c levels. Therefore, this combination can provide an alternative therapeutic option in addition to insulin in patients with very poorly controlled T2DM, without the need for multiple daily injections and dose titration, and with lower risks of weight gain and hypoglycemia.
In summary, the present results demonstrate that combination therapy with pioglitazone plus exenatide is an effective and safe therapeutic option in patients with poorly controlled T2DM, clinical symptoms of hyperglycemia, and longstanding disease who have failed to respond to treatment with metformin plus sulfonylurea. Continued follow-up will be required to ascertain how long the beneficial effects of combination therapy are maintained.
